Oncologix Tech Inc. - FORM 10-K - XML - IDEA: XBRL DOCUMENT - December 7, 2012



Attached files
FileFilename
EX-32.2 - CERTIFICATION - Oncologix Tech Inc.oncologix8312012exh322.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER - Oncologix Tech Inc.oncologix8312012exh311.htm
EX-32.1 - CERTIFICATION - Oncologix Tech Inc.oncologix8312012exh321.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER - Oncologix Tech Inc.oncologix8312012exh312.htm
EX-99 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Oncologix Tech Inc.oncologix8312012exh99.htm
EX-21 - SUBSIDIARIES OF ONCOLOGIX TECH, INC. - Oncologix Tech Inc.oncologix8312012exh21.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.R9.htm
10-K - FORM 10-K - Oncologix Tech Inc.oncologix8312012.htm
EXCEL - IDEA: XBRL DOCUMENT - Oncologix Tech Inc.Financial_Report.xls
v2.4.0.6
Consolidated Statements of Operations (USD $)
12 Months Ended 15 Months Ended
Aug. 31, 2012
Aug. 31, 2011
Aug. 31, 2012
Operating expenses:      
General and administrative $ 130,769 $ 195,067 $ 164,795
Depreciation and amortization 450 1,471 966
Total operating expenses 131,219 196,538 165,761
Loss from operations (131,219) (196,538) (165,761)
Other income (expense):      
Interest and finance charges (10,768) (14,707) (13,768)
Interest and finance charges - related parties (25,312) (18,241) (30,123)
Loss on conversion of notes payable - related parties (92,758)    (92,758)
Induced conversion expense (25,402) (6,076) (31,479)
Loss on disposal of assets (110)    (110)
Other expenses    (47)   
Total other income (expense) (154,350) (39,071) (168,238)
Loss from operations (285,569) (235,609) (333,999)
Less loss attributable to noncontrolling interest (14) (13) (17)
Net loss before income taxes (285,555) (235,596) (333,982)
Income taxes         
Net loss attributable to common shareholders $ (285,555) $ (235,596) $ (333,982)
Loss per common share, basic and diluted: $ (0.01) $ 0.00  
Weighted average number of shares outstanding - basic and diluted 54,443,649 47,915,734  

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA



This web site and associated pages are not associated with, endorsed by, or sponsored by Oncologix Tech Inc. and has no official or unofficial affiliation with Oncologix Tech Inc.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.